Best Life Sciences Tech Companies in Illinois, United States
The 57 best Life Sciences Tech companies in Illinois, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Tempus.
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Tech companies in Illinois
| # | Company | Disclosed funding | Last round | Employees | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Tempus 🦄 Developer of genomic testing and artificial intelligence tools for medicine | $1.1B | 44 mo ago | 772 | Eric Lefkofsky Founder & CEO | 2015 | Cart FunctionalityWordPressApple iCloud Mail+33 | 594 patents AI-powered medical diagnostics: imaging biomarkers, liquid biopsy genomics, and cardiac ECG analysis | — |
| 2 | Evozyne Developer of proteins using protein engineering technology | $144M | 34 mo ago | 73 | Rama Ranganathan Co-Founder & CSO | 2020 | WordPressMySQLPHP+17 | 2 patents AI-driven design of synthetic proteins for protein engineering applications | — |
| 3 | Questia Resource Library for researchers | $130M | 269 mo ago | 14 | — | 1998 | — | — | — |
| 4 | Pathos 🦄 Provider of AI based drug discovery platform for drug development | $102M | 14 mo ago | 12 | Ryan Fukushima Co-Founder | 2022 | DudaApple iCloud MailGoogle Workspace+14 | — | 2 job openings · 1 internship |
| 5 | Nucle AI AI-assisted platform for image analysis | $60M | 27 mo ago | 9 | Lotan Chorev Co-Founder and VP R&D | 2017 | — | — | — |
| 6 | PhysIQ Provider of AI-based personalized physiology data analytics platform. | $26M | 77 mo ago | 84 | — | 2005 | — | 23 patents AI-driven wearable monitoring for activity recognition and cardiovascular health analytics | — |
| 7 | Vodori Cloud based marketing solutions for life sciences companies | $12M | 57 mo ago | 38 38 → 57 (+50%) | — | 2005 | HubSpot CMS HubYouTubeEnvoy+14 | — | 1 job opening |
| 8 | BiomeSense Developer of AI-enabled technology platform for microbiome data generation and analysis | $8M | 16 mo ago | 5 | Jack Gilbert Co-Founder | 2018 | WebflowGSAPLenis+11 | 11 patents Microbiome diagnostic tools for stool sample collection and analysis | — |
| 9 | MetaMe Health Provider of digital therapeutics for gut health | $6M | 27 mo ago | 8 | — | 2015 | — | — | — |
| 10 | Rmark Bio Recommendation and management platform to help pharmaceutical companies discover academic partners | $6M | 69 mo ago | 21 | — | 2015 | — | — | — |
| 11 | Grove Biopharma Developer of AI-based drug modality platform for protein-based drugs | $4M | 14 mo ago | 7 | Geoff Duyk Co-Founder | 2020 | WebflowGSAPcore-js+10 | — | — |
| 12 | Scholar Social knowledge platform fostering community, creation, publishing, and event management | $4M | 160 mo ago | — | Bill Cope CEO & President | 2013 | RubyRuby on RailsNginx+8 | — | — |
| 13 | Halo Provider of community-based learning solutions for professionals | $3M | 45 mo ago | 7 | Kevin Leland CEO / Founder | 2016 | WebflowCannyRuby+30 | — | — |
| 14 | Cadre Research Labs Provider of 3D scanning and analysis system for Firearm Forensics | $785K | 66 mo ago | — | Ryan Lilien Founder & CSO | 2010 | — | — | — |
| 15 | ADMdx Neuroimaging diagnostic software for Alzheimer's disease and other dementias | $620K | 93 mo ago | 9 | Dawn Matthews CEO | 2010 | — | — | — |
| 16 | QCMedchain Blockchain platform providing pharmaceutical supply chain monitoring solution | $225K | 76 mo ago | — | JJ Ogrey Co-Founder & CTO | 2018 | — | — | — |
| 17 | HappiLabs Provider of virtual lab management software to manage finance and lab operations | $150K | 97 mo ago | 18 | — | 2012 | — | — | — |
| 18 | TorMagnus Pharmaceuticals Provider of bioinformatics solutions for drug development | $125K | 37 mo ago | — | John Fraser Co-Founder | 2022 | — | — | — |
Top 12 Life Sciences Tech companies in Illinois
#1
Pathos 🦄Series D · Chicago, Illinois · founded 2022 · 12 employees$102Mraised▾
Provider of AI based drug discovery platform for drug development. The company licenses or co develops clinical stage therapeutics, optimizing patient selection strategies for accelerated, biomarker driven drug development. It utilizes real world oncology data and patient derived functional genomic data to identify and validate compelling biology, aiming to develop efficacious drugs for patients with unmet needs and enhance patient outcomes.
- Apr 2025Series D$283M
- Oct 2024Series C$62M
#2
Seed · Chicago, Illinois · founded 2018 · 5 employees$8.4Mraised▾
Developer of AI-enabled technology platform for microbiome data generation and analysis. The company provides continuous, comprehensive microbiome data and AI-enabled bioinformatics. It offers GutLab technology for continuous tracking of the patient's gut microbiome throughout the treatment journey. The company's MetaBiome AI Platform transforms and analyzes the data using time-series analyses, enabling identification of clinically-relevant shifts and patterns. The platform unlocks host-microbiome interactions, such as a signature suggesting the gut microbiome may be a biomarker for active tumor burden. The company partners with scientists, institutions, and companies conducting clinical research into the gut microbiome, with a focus on personalized biomarker discovery and product development.
- Feb 2025Grant (prize money)$1.1M
- Feb 2023Seed$6.2M
- Jun 2021Grant (prize money)$294.4K
- Jan 2021Grant (prize money)$255.7K
#3
Series A · Chicago, Illinois · founded 2020 · 7 employees$4Mraised▾
Developer of AI-based drug modality platform for protein-based drugs
- Apr 2025Series A$30M
- Jul 2023Grant (prize money)$246.7K
- May 2021Seed$4M
#4
Tempus 🦄Public · Chicago, Illinois · founded 2015 · 772 employees$1.1Braised▾
Developer of genomic testing and artificial intelligence tools for medicine. This organization provides molecular profiling, algorithmic diagnostic models, and digital pathology services to assist in clinical decision-making. The technology integrates clinical data with sequencing results to identify therapeutic options and potential clinical trial matches. These tools support oncology, neurology, psychiatry, cardiology, and radiology by analyzing biological data to assist in patient care and drug development. The platform facilitates the identification of biomarkers and provides insights into disease progression and treatment responses.
- Oct 2022Series G—
- Oct 2022Conventional Debt—
- Dec 2020Series G$200M
- Mar 2020Series G$100M
#5
Series B · Chicago, Illinois · founded 2017 · 9 employees$60Mraised▾
AI-assisted platform for image analysis. The platform enables researchers to analyze and predict the tissue and cell architecture from pathology slides. It helps with the discovery of pathology-based spatial biomarkers.
- Apr 2024Series B$14M
- Mar 2022Series B$33M
- Jul 2020Series A$6.5M
- Mar 2018Seed$5M
#6
Series B · Chicago, Illinois · founded 2020 · 73 employees$144.4Mraised▾
Evozyne has developed novel proteins using protein engineering technology. The company uses machine learning, statistical techniques with high throughput gene synthesis and screening technology to build predictive models of sequence-function relationships for a family of proteins for synthesis, and characterizing of the proteins.
- Sep 2023Series B$81M
- Sep 2023Conventional Debt—
- Apr 2021Series B$54.2M
- Apr 2020Series A$9.2M
#7
Seed · Chicago, Illinois · founded 2015 · 8 employees$6Mraised▾
MetaMe Health provides digital therapeutics for gastrointestinal conditions. Regulora, the company's flagship platform, provides relief by digitizing a standardized Brain-Gut therapy approach that has been clinically proven to be effective in reducing Irritable Bowel Syndrome (IBS) symptoms. The platform is a software-based product that engages patients, tracks adherence, facilitates clinician engagement, and safely delivers consistent health outcomes in randomized controlled clinical trials.
- Mar 2024Conventional Debt$140.5K
- May 2023Conventional Debt$235K
- Mar 2022Seed$2.2M
- Nov 2021Conventional Debt$65K
#8
Acqui-Hired · Chicago, Illinois · founded 1998 · 14 employees$130Mraised▾
Questia Media is a provider of copyrighted information and educational resources. The platform provides a research library with unlimited access to tens of thousands of scholarly books and journals. Claims to be used by students, instructors, hobbyists, enthusiasts and lifelong learners in many countries. Acquired by Cengage Learning in January 2010. Offers acess to 76K+ books from 300+ publishers and 1M+ articles from journals, magazines and newspapers in in 200+ countries. Founder has leadership experience in a public company.
- Jan 2004Venture Debt$10M
- Aug 2000Series B$90M
- Mar 2000Series A$40M
#9
Series B · Naperville, Illinois · founded 2005 · 84 employees$26.4Mraised▾
PhyIQ is an AI-based personalized physiology data analytics platform designed to track vital signs and detect clinically relevant changes against a personal baseline. The company offers to differentiate itself by providing health updates based on a patient's own health background rather than comparison with the broader population. PhysIQ technology is an early warning platform and not a diagnostic tool.
- Jan 2020Series B$500K
- Nov 2019Series B$6M
- Jun 2017Series B$8M
- Feb 2016Series A$3.6M
#10
Series A · Chicago, Illinois · founded 2005 · 38 employees$11.7Mraised▾
Cloud based marketing solutions for life sciences companies aiming at the promotional review process. By enabling real time collaborative review, making in flight work visible, and integrating with content delivery platforms, Pepper Flow helps life sciences companies streamline the MLR process so they can focus on planning and executing content.
- Sep 2021Series A$7.5M
- Apr 2020Series A$3M
- Apr 2018Seed$1.2M
#11
Seed · Chicago, Illinois · founded 2016 · 7 employees$2.6Mraised▾
Provider of community-based learning solutions for professionals. It enables finding opportunities, collaboration with the company, solutions to the problem, submitting proposals, receive feedback, and more.
- Sep 2022Seed$2.6M
#12
Acqui-Hired · Chicago, Illinois · founded 2015 · 21 employees$6Mraised▾
rMark Bio offers intelligent recommendation and management platform to help pharmaceutical companies discover academic partners. Its Collaboration Recommendation Engine (CoRE) platform uses natural language processing to analyse information about research activities of academic scientists. It captures raw data from various sources including publications, grants, websites which is then normalised and processed. The platform calculated rMark score and provides ranked list for reporting. Advisor is the first tablet application powered by rMark Bio’s CoRE. It can be used to search information, manage connections, provides dashboards and alerts, and custom reports based on keyword searches.
- Oct 2020Seed$2.8M
- Feb 2019Seed$1.5M
- Jan 2018Conventional Debt—
- Jan 2018Seed$1.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Illinois is moving
A read on the academic research around Biotechnology in Illinois — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 100 papers.
University of Illinois institutions lead Illinois biotechnology research, focusing predominantly on CRISPR, genetic engineering, and microbial engineering, with an optimistic yet cautiously mixed stance (0.43).
- University of Illinois Urbana-Champaign56
- University of Illinois Chicago18
- University of Illinois System7
- Southern Illinois University School of Medicine4
- Western Illinois University4
- Gene1→4
- Gene8
- Biomass (ecology)3
- Plasmid3
- mCherry3
- Polymerase chain reaction3
- Agriculture3
- Production (economics)3
- Public health3
- Food safety3
- Microbiome3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.